The Platinum Healthcare LLC – FDA Warning Letter, Oct 1, 2026

The FDA issued a Warning Letter on October 1, 2026, to The Platinum Healthcare LLC following a July 2026 review of the company"s website. The agency identified significant violations regarding the marketing of "Sycosis" and "Syphillinum," which are sold as over-the-counter treatments for conditions associated with sexually transmitted infections (STIs), specifically gonorrhea and syphilis. According to the FDA, these products are unapproved new drugs under the Federal Food, Drug, and Cosmetic (FD&C) Act. The agency expressed concern that marketing unproven STI treatments directly to consumers presents a serious public health risk, as individuals might forgo essential medical care, leading to complications like infertility or sepsis. While the products are labeled as homeopathic, the FDA noted that such drugs remain subject to the same statutory requirements for safety and efficacy as other pharmaceutical products. The Platinum Healthcare LLC must investigate the root causes of these violations and implement corrective measures to ensure sustained compliance. The company is required to submit a written response within fifteen business days detailing the steps taken to address the violations and prevent their recurrence. Failure to rectify these issues may result in legal actions, including product seizure or injunctions.